Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer
2016-001263-37Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- May 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in urothelial carcinoma (UC) (2 arms), sponsored by Ghent University Hospital. Primary endpoints: Safety and dose-limiting toxicity of SBRT with pembrolizumab and Tumor response in non-irradiated metastases. Started May 2016; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2016-001263-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001263-37.